Log In Sign up
The largest database of trusted experimental protocols

On target plus sirna non targeting control

Manufactured by Horizon Discovery
Visit Supplier

The ON-TARGET Plus siRNA non-targeting control is a synthetic small interfering RNA (siRNA) product developed by Horizon Discovery. It is designed to serve as a negative control in gene silencing experiments using RNA interference (RNAi) technology. The core function of this product is to provide a non-targeting siRNA sequence that does not have complementarity to any known gene in the target organism, allowing researchers to assess off-target effects and establish baseline cellular responses.

Automatically generated - may contain errors

Lab products found in correlation

On target plus sirna targeting brca1, by Horizon Discovery (2 mentions) Rad51, by Horizon Discovery (2 mentions) Dharmafect 2, by Horizon Discovery (2 mentions) Brca2, by Horizon Discovery (2 mentions)

Spelling variants of this product

Control siRNA (209 citations) SiRNAs (161 citations) Non-targeting control siRNA (92 citations) Non-targeting siRNA (74 citations) ON-TARGET (46 citations) SiRNA targeting (10 citations) On-Target Plus non-targeting (5 citations) Non-target control siRNA (5 citations) Non-Target (5 citations) Non-target siRNA (4 citations)

2 protocols using on target plus sirna non targeting control

1

Targeted siRNA Knockdown Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
siRNA transfections were carried out with Dharmafect 2 (GE Dharmacon) per manufacturers protocol with final siRNA concentration at 20 nM for all assays. siRNAs used were ON-TARGET Plus siRNA targeting BRCA1 (GE Dharmacon, L-003461), RAD51 (GE Dharmacon, L-003530), BRCA2(L-003462, GE Dharmacon), SDHB (GE Dharmacon, L-011773), FH (L-009512, GE Dharmacon) and the ON-TARGET Plus siRNA non-targeting control (GE Dharmacon, D-001810)
Sulkowski P.L., Sundaram R.K., Oeck S., Corso C.D., Liu Y., Noorbakhsh S., Niger M., Boeke M., Ueno D., Kalathil A.N., Bao X., Li J., Shuch B., Bindra R.S, & Glazer P.M. (2018). Krebs Cycle-Deficient Hereditary Cancer Syndromes are Defined by Homologous Recombination DNA Repair Defects. Nature genetics, 50(8), 1086-1092.
+ Open protocol
+ Expand
2

Targeted siRNA Knockdown Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
siRNA transfections were carried out with Dharmafect 2 (GE Dharmacon) per manufacturers protocol with final siRNA concentration at 20 nM for all assays. siRNAs used were ON-TARGET Plus siRNA targeting BRCA1 (GE Dharmacon, L-003461), RAD51 (GE Dharmacon, L-003530), BRCA2(L-003462, GE Dharmacon), SDHB (GE Dharmacon, L-011773), FH (L-009512, GE Dharmacon) and the ON-TARGET Plus siRNA non-targeting control (GE Dharmacon, D-001810)
Sulkowski P.L., Sundaram R.K., Oeck S., Corso C.D., Liu Y., Noorbakhsh S., Niger M., Boeke M., Ueno D., Kalathil A.N., Bao X., Li J., Shuch B., Bindra R.S, & Glazer P.M. (2018). Krebs Cycle-Deficient Hereditary Cancer Syndromes are Defined by Homologous Recombination DNA Repair Defects. Nature genetics, 50(8), 1086-1092.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!